CIBC Private Wealth Group
APLS

CIBC Private Wealth Group’s Apellis Pharmaceuticals APLS Stock Holding History

CIBC Private Wealth Group’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$8.62K Sell
343
-34
-9% -$798 ﹤0.01% 2468
2025
Q3 		$8.53K Sell
377
-3,127
-89% -$72.9K ﹤0.01% 2443
2025
Q2 		$60.7K Sell
3,504
-15,360
-81% -$284K ﹤0.01% 1592
2025
Q1 		$353K Hold
18,864
– – ﹤0.01% 912
2024
Q4 		$623K Sell
18,864
-546
-3% -$16.4K ﹤0.01% 807
2024
Q3 		$560K Buy
19,410
+1,490
+8% +$55.2K ﹤0.01% 839
2024
Q2 		$663K Hold
17,920
– – ﹤0.01% 741
2024
Q1 		$1.07M Buy
17,920
+10
+0.1% +$637 ﹤0.01% 660
2023
Q4 		$1.07M Hold
17,910
– – ﹤0.01% 616
2023
Q3 		$681K Sell
17,910
-52,870
-75% -$2.32M ﹤0.01% 685
2023
Q2 		$6.45M Buy
70,780
+13,795
+24% +$1.19M 0.01% 369
2023
Q1 		$3.76M Buy
+56,985
New +$3.29M 0.01% 427

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

CIBC Private Wealth Group's APLS Position: Q4 2025 in Review

CIBC Private Wealth Group reduced its Apellis Pharmaceuticals (APLS) stake by 9% in Q4 2025, selling an estimated $798 and leaving 343 shares worth $8.62K. The position accounts for ﹤0.01% of the portfolio, ranked #2468.

CIBC Private Wealth Group first reported a position in APLS in Q1 2023 and has held it in 12 quarters since. The position peaked at $6.45M in Q2 2023. 279 funds tracked by Wall St. Rank hold APLS as of Q4 2025.

  • CIBC Private Wealth Group held 343 shares of Apellis Pharmaceuticals worth $8.62K as of Q4 2025.
  • CIBC Private Wealth Group sold 34 Apellis Pharmaceuticals shares in Q4 2025, an estimated $798.
  • Apellis Pharmaceuticals made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #2468 holding.
  • CIBC Private Wealth Group first reported a position in Apellis Pharmaceuticals in Q1 2023 and has held it in 12 quarters since.
  • CIBC Private Wealth Group's Apellis Pharmaceuticals position peaked at $6.45M in Q2 2023.
  • 279 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.